463 patents
Page 22 of 24
Utility
Method for Determining Lymphoma Type
1 Apr 20
In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements.
Louis M. Staudt, Christian Steidl, Anja Mottok, George W. Wright, David William Scott, Lisa M. Rimsza, Andreas Rosenwald, Randy Gascoyne, Timothy Greiner, Dennis Weisenburger, Erlend B. Smeland, Jan Delabie, Elias Campo Guerri, German Ott, Rita Braziel, Elaine S. Jaffe, Kai Fu, Wing C. Chan, Joo Song, James R. Cook
Filed: 12 Dec 19
Utility
Methods of treating advanced prostate cancer
30 Mar 20
Provided herein are methods for treating metastatic prostate cancer using anti-androgen compounds and radionuclide-labeled androgens.
Zijie Sun, David Horne, Junfeng Li, John E. Shively, Jun Xie
Filed: 29 Apr 18
Utility
Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
30 Mar 20
A method of preventing, controlling or treating CMV infections with a vaccine comprising an immunologically effective amount of a fusion cytomegalovirus (CMV) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of Immediate-Early Gene-1 or Immediate-Early Gene-2 (IEfusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine.
Don Diamond, Zhongde Wang
Filed: 7 May 17
Utility
Targeting glioblastoma stem cells through the TLX-TET3 axis
30 Mar 20
Methods and compositions capable of modulating activity of TLX (NR2E1), a nuclear receptor essential for neural stem cell self-renewal are provided.
Yanhong Shi, Qi Cui, Su Yang
Filed: 12 Jan 17
Utility
Methods for In Vivo Expansion of CD8+ T Cells and Prevention or Treatment of GVHD
25 Mar 20
Disclosed herein are methods of preventing and treating acute GVHD and chronic GVHD after hematopoietic cell transplantation (HCT), as well as methods of in vivo augmenting expansion of donor CD8+ T cells in the lymphoid tissues in vivo after HCT and methods of augmenting recipient tissue expression of programmed death-ligand 1 (PD-L1, or B7H1) after HCT.
Defu ZENG
Filed: 15 Aug 19
Utility
Methods for Manufacturing T Cells Expressing of Chimeric Antigen Receptors and Other Receptors
25 Mar 20
A method for preparing T cell populations for use in CAR T cell therapy and other immune cell therapies is described.
Darya Alizadeh, Christine E. Brown, Stephen J. Forman
Filed: 30 Nov 17
Utility
STEM CELL MODEL OF APOE GENOTYPE AND Abeta42-DEPENDENT NEURODEGENERATION AND METHODS OF USING THE SAME
25 Mar 20
Provided is an isolated cell including a modified amyloid beta precursor protein (APP) gene.
Paul M. SALVATERRA, Jiing-Kuan YEE
Filed: 14 Jul 19
Utility
Recombinant adeno-associated vectors for targeted treatment
23 Mar 20
Novel adeno-associated virus (AAV) vectors in nucleotide and amino acid forms and uses thereof are provided.
Saswati Chatterjee, Laura Jane Smith, Kamehameha Wong
Filed: 29 Oct 17
Utility
Synthetic conjugate of CpG DNA and T-help/CTL peptide
23 Mar 20
Highly effective vaccine compositions are constructed according to the methods of this invention.
Don J. Diamond
Filed: 25 Apr 18
Utility
Txnip-trx Complex Inhibitors and Methods of Using the Same
18 Mar 20
Disclosed herein, inter alia, are compounds and methods for inhibiting the thioredoxin-thioredoxin-interacting-protein (TXNIP-TRX) complex.
Rama Natarajan, Feng Miao, Nagarajan Vaidehi, Supriyo Bhattacharya, Adrien Beau Larsen
Filed: 12 Sep 19
Utility
Chimeric antigen receptor compositions
16 Mar 20
Provided herein are compositions, which exhibit diagnostic capabilities and allow to rapidly add functionality to adoptive immunotherapy.
John C. Williams, Christine Brown
Filed: 14 Feb 17
Utility
ERR modulators and uses thereof
16 Mar 20
Disclosed herein, inter alia, are compositions and methods useful for treating non-alcoholic fatty liver diseases.
Donna D. Yu, Barry M. Forman
Filed: 10 Apr 18
Utility
Twist Signaling Inhibitor Compositions and Methods of Using the Same
11 Mar 20
The present invention relates to compositions comprising TWIST signaling inhibitors and optionally one or more anti-cancer agents, and methods of using the compositions for the treatment of cancer.
Carlotta A. GLACKIN, John J. ROSSI, Jeffrey I. ZINK, Fuyuhiko TAMANOI, Cai M. ROBERTS, James FINLAY
Filed: 21 Nov 19
Utility
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
9 Mar 20
In one embodiment, a single modality cancer immunotherapy regimen that includes a therapeutic composition is provided.
Don J. Diamond, Edwin Manuel
Filed: 14 Oct 18
Utility
Mva Vaccine for Delivery of a UL128 Complex and Preventing CMV Infection
4 Mar 20
In one embodiment, an expression system for expressing a UL128 complex is provided herein.
Don J. DIAMOND, Felix WUSSOW
Filed: 11 Aug 19
Utility
Antibody Variable Domains and Antibody Constructs
4 Mar 20
Provided herein are, inter alia, compositions and methods for the treatment of cancer.
Hong QIN, Larry W. KWAK, Guowei WEI
Filed: 3 May 18
Utility
Epstein-barr Virus Antibodies and Uses Thereof
19 Feb 20
Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more epitopes of EBV gp350 and neutralize EBV infection.
Javier Gordon OGEMBO, Lorraine Zvichapera MUTSVUNGUMA, Alison Evelynn ONDRUS
Filed: 26 Apr 18
Utility
Use of Endogenous Viral Vaccine In Chimeric Antigen Receptor T Cell Therapy
19 Feb 20
Provided herein are, inter alia, methods and compositions including T cells expressing (i) a recombinant CAR protein which includes a peptide binding site and is capable of specifically binding cancer-specific antigens and (ii) a T cell receptor specific for a viral antigen (e.g., a CMV pp65 protein).
John C. WILLIAMS, Christine BROWN, Don J. DIAMOND
Filed: 18 Oct 17
Utility
DNA2 inhibitors for cancer treatment
17 Feb 20
Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
Binghui Shen, Judith Campbell, Li Zheng, Hongzhi Li, David Horne, Jun Xie, Kenneth Karanja
Filed: 29 Nov 18
Utility
P53-TARGETING Vaccines and PD-1 Pathway Inhibitors and Methods of Use Thereof
12 Feb 20
The disclosure provides, inter alia, methods and materials involved in treating cancer using a p53 vaccine in combination with a PD-1 pathway inhibitor.
Don J. DIAMOND
Filed: 7 Dec 17